直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Expert Testimony Deemed Admissible Despite Reliance on Novel, Unpublished Methodology

September 24, 2015

Authored and Edited by Elizabeth D. Ferrill; Jeff T. Watson

In Summit 6, LLC v. Samsung Electronics Co., Nos. 13-1648, -1651 (Fed. Cir. Sept. 21, 2015), the Federal Circuit affirmed the district court’s denial of Samsung’s JMOL motion to exclude testimony from Summit 6’s expert, Paul Benoit.  Benoit testified that Samsung would have agreed to pay $29 million to license a patent related to photo-sharing, while Samsung argued that the feature was not worth more than $1.5 million.

On appeal, Samsung argued that: (1) Benoit’s methodology was unpublished, created specifically for this litigation, and never before employed by Benoit or by another expert; (2) Benoit’s premise that a feature’s use is proportional to its value was incorrect; and (3) Benoit’s use of surveys was unreliable because he was not a survey expert.

While Daubert holds that a court may consider whether a methodology has been tested, published, or generally accepted, the Federal Circuit held that the admissibility inquiry is flexible and centers on whether the methodology is reliable and the data used is sufficiently tied to the facts of the case.  The Court held that to the extent Benoit’s credibility, data, or factual assumptions have flaws, these flaws go to the weight of the evidence, not to its admissibility.

 

Contacts

Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Federal Circuit IP Blog

Federal Circuit Affirms § 102(b) Invalidity; Source Code Commands Are Not Hearsay

May 14, 2026

Federal Circuit IP Blog

When “and” and “e.g.” Matter: Federal Circuit Revives VLSI vs. Intel Case

May 14, 2026

Articles

D. Mass. Patent Litigation Update, March 2026

D. Mass. Patent Litigation Update: March 2026

May 4, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP